PDCD1 and head and neck cancer: These findings aligned with early signals from phase I radio-immunotherapy platforms in rectal and head-and-neck cancers, which also reported acceptable safety profiles when PD-1/PD-L1 agents were intercalated with moderately hypofractionated fields (40, 41).